IPH2201
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gynecologic Cancer
Conditions
Gynecologic Cancer
Trial Timeline
Sep 17, 2015 → Nov 12, 2019
NCT ID
NCT02459301About IPH2201
IPH2201 is a phase 1 stage product being developed by Innate Pharma for Gynecologic Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02459301. Target conditions include Gynecologic Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02459301 | Phase 1 | Completed |
| NCT02331875 | Phase 1/2 | Terminated |
Competing Products
13 competing products in Gynecologic Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| IMGN151 + Carboplatin + Bevacizumab + Olaparib | AbbVie | Phase 2 | 52 |
| Durvalumab + Tremelimumab | AstraZeneca | Phase 1 | 33 |
| Pembrolizumab | Merck | Phase 1 | 33 |
| Atezolizumab + Rucaparib | Roche | Phase 1 | 33 |
| Vigil + Atezolizumab | Roche | Phase 2 | 52 |
| darbepoetin alfa + recombinant human erythropoietin (rHuEPO) | Amgen | Phase 2 | 51 |
| Oral apixaban + Subcutaneous enoxaparin | Bristol Myers Squibb | Phase 2 | 51 |
| AK112 | Akeso | Phase 2 | 51 |
| Ciprofol + Propofol | Haisco Pharmaceutical Group | Phase 3 | 74 |
| Floseal | Baxter | Phase 3 | 74 |
| FloSeal application | Baxter | Pre-clinical | 20 |
| Neoantigen specific TCR-T cell drug product + Aldesleukin (IL-2) | Alaunos Therapeutics | Phase 1/2 | 33 |
| Neoantigen specific TCR-T cell drug product | Alaunos Therapeutics | Pre-clinical | 15 |